Affymax (Affymax) FCF Margin %

: -3,469.05% (As of Jun. 2014)

View and export this data going back to 2006. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Affymax's Free Cash Flow for the three months ended in Jun. 2014 was $-1.46 Mil. Affymax's Revenue for the three months ended in Jun. 2014 was $0.04 Mil. Therefore, Affymax's FCF Margin % for the quarter that ended in Jun. 2014 was -3,469.05%.

As of today, Affymax's current FCF Yield % is -32,176.92%.

The historical rank and industry rank for Affymax's FCF Margin % or its related term are showing as below:

AFFY' s FCF Margin % Range Over the Past 10 Years
Min: -19919.05 Med: 0 Max: 0
Current: -19919.05

AFFY's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -149.715 vs AFFY: -19919.05

Affymax FCF Margin % Historical Data

The historical data trend for Affymax's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

FCF Margin %

-70.95

-44.40

-153.46

-43.70

-4,918.85

Affymax Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
FCF Margin %																-6,962.10	-	-	-	-3,469.05

Competitive Comparison

For the Biotechnology subindustry, Affymax's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affymax FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Affymax's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Affymax's FCF Margin % falls into.

Affymax FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Affymax's FCF Margin for the fiscal year that ended in Dec. 2013 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2013 )	/	Revenue (A: Dec. 2013 )
	=	-67.339	/	1.369
	=	-4,918.85 %

Affymax's FCF Margin for the quarter that ended in Jun. 2014 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2014 )	/	Revenue (Q: Jun. 2014 )
	=	-1.457	/	0.042
	=	-3,469.05 %

Affymax FCF Margin % Related Terms

Thank you for viewing the detailed overview of Affymax's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Executives

John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson	officer: Chief Financial Officer	8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp	officer: Chief Commercial Officer	4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte	director
Karin L Walker	officer: VP, Finance & CAO	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton	director
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland	officer: EVP, Corp. Development and CFO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris	director, officer: CEO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010